Proskauer, Jones Day Rep Celgene In $3B Abraxis Buy
Celgene Corp. said Wednesday that it had penned a deal to acquire biotechnology firm Abraxis BioScience Inc. for an upfront payment of $2.9 billion in cash, a move the company said...To view the full article, register now.
Already a subscriber? Click here to view full article